CIAO!™ Technology Maximizes Selectivity of Conditionally Active AntibodiesS an Diego, Calif. – October 14, 2014 – BioAtla®, a global biotechnology company focused on the development of Conditionally Active Biologics, today announced that the United States Patent and Trademark Office has issued to BioAtla U.S. Patent No. 8,859,467, for its proprietary Comprehensive Integrated Antibody Optimization technology platform.
The CIAO! technology platform allows for antibody candidate development in a native cellular environment that generates the best collection of lead candidates that optimize downstream expression yields and in vivo translation of function, thereby increasing the likelihood of preserving selected therapeutic activities in the final drug.
“CABs can be designed as monoclonal antibodies, antibody drug conjugates, CAR-T cells or other therapeutics to target specific tissues in cancerous or distressed conditions associated with unique microenvironments in the body. CAB antibodies are a disruptive technology for the development of a powerful new class of immunotherapeutics and are prime examples of novel potential product opportunities that benefit from the use of CIAO!-based processes.” BioAtla employs CIAO!™ technology in all of its internal development programs for its growing list of pipeline antibody candidates.
BioAtla has successfully utilized CIAO! in dozens of antibody programs over the past several years including the licensing in early 2014 of an antibody directed at a novel validated target for the treatment of inflammatory bowel diseases and colorectal cancer.
ABOUT THE CIAO!™ TECHNOLOGY PLATFORM The development of novel therapeutic antibodies is increasingly employing the power of evolution to discover molecules with selected characteristics.
These proteins can be monoclonal antibodies, antibody drug conjugates, CAR-T cells, or other therapeutic proteins designed with functions dependent on changes in microphysiological conditions.
The higher selectivity resulting from CAB antibody generation is expected to capitalize on the attractiveness of such previously unavailable targets and increase the effectiveness of most therapeutics relative to traditional antibody approaches.